Cetuximab Erbitux®
The SHIKARI® Cetuximab portfolio provides one quantitative free-drug assay plus quantitative and qualitative anti-cetuximab antibody assays for human serum or plasma.
Why Cetuximab is relevant to biological-drug monitoring research
Cetuximab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Cetuximab is a chimeric IgG1 monoclonal antibody that binds the extracellular domain of EGFR and inhibits ligand-driven receptor signalling. Source ↗
Approved Indications
EMA-authorised uses include selected RAS wild-type, EGFR-expressing metastatic colorectal cancer and squamous-cell carcinoma of the head and neck in defined treatment settings. EMA source ↗
Weekly-Regimen Exposure
FDA pharmacokinetic data for the historical weekly regimen (400 mg/m² loading, then 250 mg/m² weekly) report:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three verified Cetuximab research assays
Ligand-binding, sandwich-principle ELISA for quantitative analysis of free cetuximab in human serum or plasma.
Quantitative ELISA for anti-cetuximab antibodies in human serum or plasma, including the assay-specific confirmation-reagent procedure.
Qualitative ELISA for positive or negative assessment of anti-cetuximab antibodies in human serum or plasma according to assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-CET | CET-FD-ERB | Quantitative | Free cetuximab | Human serum / plasma | 10 µL | 70 min | LOD 30 ng/mL; LOQ 100 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATC | CET-QNS-ERB | Quantitative | Anti-cetuximab antibodies | Human serum / plasma | 20 µL | 140 min | LOD 30 ng/mL; LOQ 31.25 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATC | CET-QLS-ERB | Qualitative | Anti-cetuximab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Publications Using SHIKARI® Cetuximab Kits 4
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Planning a Cetuximab research study?
Matrix Biotek can help identify the appropriate Cetuximab assay and prepare regional quotation and delivery information.